Core Points - Neurothera Labs Inc. held its annual and special meeting of shareholders on January 8, 2026, where key decisions were made regarding the company's governance and future plans [1] Group 1: Shareholder Decisions - All nominee directors listed in the management information circular dated December 4, 2025, were elected as directors [2] - Shareholders voted to appoint Dale Matheson Carr-Hilton Labonte LLP as auditors for the upcoming year and authorized the directors to fix their remuneration [2] - A consolidation of common shares was authorized, allowing for a potential consolidation of one post-consolidation share for up to one hundred pre-consolidation shares, subject to the directors' discretion and market conditions [3] - The adoption of a 20% fixed equity incentive plan was approved, pending final approval from the TSX Venture Exchange [4] Group 2: Company Overview - Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [5]

Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a patent in Israel for a proprietary combination of opioids and N-acylethanolamines, aimed at enhancing opioid efficacy while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening NeuroThera's global intellectual property protection [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance the analgesic effects of opioids like oxycodone, allowing for effective pain relief at lower doses [3][5]. - Pre-clinical studies demonstrated that the combination of oxycodone and PEA not only improved pain relief but also reduced adverse psychoactive effects associated with oxycodone [5]. Group 2: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant demand for opioid medications [6]. - The opioid-sparing effect of NeuroThera's combination may lead to lower required dosages of opioids, potentially mitigating risks such as addiction and respiratory depression [7]. Group 3: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its subsidiary NeuroThera Labs Inc., which is engaged in creating novel therapeutics for central nervous system disorders [9][10]. - The company is also involved in developing cannabinoid-based pharmaceuticals, with ongoing programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [9].

Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].

Core Viewpoint - Blue Lagoon Resources Inc. has made its first sale of gold and silver from the Dome Mountain project, marking a significant transition from a pre-revenue to a revenue-generating mining company [5][6]. Group 1: Sales and Financials - The company expects to receive C$970,000 from the initial delivery of approximately 1,000 tonnes of mineralized material to Nicola Mining for processing [2][3]. - This payment is an advance on the first shipment, with final settlement pending processing and subject to adjustments based on assays and metal prices [3]. Group 2: Operations and Development - Underground development, production, and shipments are set to resume in the first week of January following a holiday break [4]. - The company views this sale as a milestone, indicating its focus on advancing development and production activities [6]. Group 3: Strategic Plans - Blue Lagoon plans to reinvest internally generated cash flow into near-mine and regional exploration starting in H1 2026 to expand its resource base [9]. - The company is committed to sustainability and community engagement while aiming to become a profitable gold producer [10]. Group 4: Equity Incentives - The company has granted 3,000,000 restricted share units and 200,000 stock options to directors and management, with stock options exercisable at $0.66 per share [7].

Core Insights - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. will acquire a 55% equity interest in a pioneering quantum computing bio data company, with the transaction involving the issuance of common shares equivalent to 40% of NeuroThera's share capital [1][3] Group 1: Acquisition Details - The acquisition is based on a non-binding term sheet and is subject to due diligence, negotiation of definitive agreements, and regulatory approvals [1][3] - The Target Company specializes in quantum-enabled clinical analytics, which aims to enhance the efficiency of bio data storage, manipulation, and analysis [2] Group 2: Quantum Computing Impact - Quantum computing principles such as superposition and entanglement are expected to revolutionize clinical trials by integrating quantum intelligence with bioinformatics [2] - This innovative approach aims to unlock precision and speed in medical research and development, potentially leading to superior machine learning performance [2] Group 3: Company Background - SciSparc Ltd. focuses on developing cannabinoid pharmaceuticals through its subsidiary NeuroThera, which is engaged in drug development programs targeting conditions like Tourette syndrome and Alzheimer's disease [4] - NeuroThera Labs Inc. is dedicated to creating novel therapeutics for central nervous system disorders and other underserved health conditions [5]

Core Insights - Neurothera Labs Inc. has entered into a non-binding term sheet to acquire a 55% equity interest in a quantum computing bio data company, which is expected to enhance clinical analytics capabilities [1][3] - The acquisition involves issuing common shares of Neurothera equal to 40% of its common shares on a non-diluted post-transaction basis to the selling shareholders of the target company [1] Company Overview - Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [4] Industry Implications - The integration of quantum computing principles in bio data analytics could revolutionize the field by enabling faster computations and superior machine learning performance, potentially redefining clinical trials and enhancing medical research and development [2]

Core Insights - SciSparc Ltd. has signed a binding term sheet to acquire patents, trademarks, and intellectual property rights for innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. [1][4] Company Overview - SciSparc operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. Product Details - The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2]. Market Strategy - Following Xylo's successful commercialization in Greater China, SciSparc aims to replicate this model in high-growth regions like North America, Europe, and Latin America by forming exclusive partnerships with regional distributors [3]. Financial Terms of Acquisition - The acquisition will involve SciSparc issuing shares to Xylo, representing 19.99% of the company's issued and outstanding share capital upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5].

Core Viewpoint - SciSparc Ltd. is strategically expanding its operations by acquiring endoscopy intellectual property from Xylo Technologies Ltd., moving beyond its core neuroscience pipeline into medical device commercialization [1]. Strategic IP Acquisition - SciSparc has signed a binding term sheet to acquire a portfolio of patents, trademarks, and know-how related to advanced endoscopic imaging systems, focusing on the MUSE platform, a single-use device for transoral fundoplication procedures aimed at treating gastroesophageal reflux disease (GERD) [2]. Expansion into Procedural Technology - Through its majority-held subsidiary NeuroThera Labs Inc., SciSparc has primarily focused on clinical-stage therapies. The acquisition broadens its exposure into procedural technology for gastrointestinal treatment markets [3]. MUSE Commercial Potential - The MUSE device facilitates minimally invasive treatment for GERD patients. SciSparc intends to leverage Xylo's previous commercialization success in Greater China to penetrate North America, Europe, and Latin America. Xylo had previously secured a licensing deal in 2019 with a Shanghai-based distributor, receiving $3 million upfront, which SciSparc plans to replicate through exclusive regional partnerships [4]. Share-Based Consideration Structure - Under the terms of the acquisition, SciSparc will issue equity equal to 19.99% of its outstanding shares upon closing, with the option to substitute part or all of that with pre-funded warrants. This acquisition grants SciSparc direct ownership of the technology and commercialization rights, potentially supporting future licensing revenue and enhancing its diversification strategy [5]. Price Action - Following the announcement, SciSparc shares increased by 29.10%, reaching $3.15, while the stock is near its 52-week low of $1.75 [6].

Core Viewpoint - SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property rights related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition aims to enhance SciSparc's capabilities in the medical device market, particularly for treating gastroesophageal reflux disease (GERD) [1][4]. Company Overview - SciSparc Ltd. operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. - The company is engaged in drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder (ASD) [7]. Acquisition Details - The acquisition includes the complete portfolio of intellectual property rights associated with the MUSE™ system, which is designed for transoral fundoplication, a minimally invasive procedure for GERD treatment [2][4]. - In exchange for the acquired assets, SciSparc will issue shares representing 19.99% of its outstanding share capital to Xylo upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5]. - SciSparc plans to replicate Xylo's successful commercialization model from Greater China to high-growth regions such as North America, Europe, and Latin America through exclusive partnerships with regional distributors [3].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]